EYPT stock news · EyePoint Pharmaceuticals

JonesTrading changed EyePoint Pharmaceuticals' rating to Hold after its stock fluctuated and its DURAVYU trial didn't succeed.

EyePoint is cutting its staff by 53% and stopping clinical trials to change its focus.

EyePoint's wet AMD study missed its main vision goal, leading to early trial stops and plans to cut 53% of its workforce. DME progress helps, but the setback leaves its outlook weaker.

12 health care companies are seeing big changes in their stock prices today.

The article reports a fall in EyePoint shares but gives no company news explaining it. The share move alone does not change what the article says about the company.

EyePoint, Inc. shares its financial situation and plans to cut its workforce by about 53%.

EyePoint will end its pivotal wet AMD trials early and cut about 53% of its staff. That loss outweighs its increased focus on DME.

12 health care stocks are changing a lot before the market opens on Monday.

EyePoint shares fell 80% before trading began. The story gives no reason or company news, so the drop alone does not change the company's business outlook.

Xenon Pharmaceuticals, Steel Dynamics, Nucor, and other major stocks dropped in early trading on Friday.

EyePoint fell 4% to $3.83 in pre-market trading after a prior-day jump; the story lists intraday moves only and does not alter EyePoint's business picture.

Three major downgrades for Wednesday emerge as this Toast analyst shifts to a bearish stance.

TD Cowen cut EyePoint from Buy to Hold and deeply reduced the price target, indicating substantially weaker analyst expectations.

Forecasts for EyePoint are significantly downgraded by analysts.

EyePoint Pharmaceuticals announced mixed results from its Phase 3 LUGANO trial for DURAVYU, leading to significant downgrades from analysts. While secondary endpoints showed promise, the failure to meet the primary endpoint has raised concerns, prompting analysts to lower their price targets substantially, which could negatively affect investor confidence and stock performance.

Ocular Therapeutix shares rise on Monday amid EyePoint's trial setbacks.

EyePoint's failure to meet primary endpoints in its trial negatively impacts its stock and market perception.

EyePoint shares tumble following inconclusive primary results from blindness treatment trial.

EyePoint Inc. experienced a dramatic decline in stock price after the release of topline results from its Phase 3 LUGANO clinical trial for DURAVYU, which failed to meet its primary endpoint due to a confounding patient subgroup. Despite some positive secondary outcomes, the market reacted negatively to the primary data, leading to a 70.24% drop in share price.